TNF Inhibitor denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for tnf inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Applied Step Therapy to Your TNF Inhibitor — and How to Overcome It

Tumor Necrosis Factor (TNF) inhibitors are the most commonly step-therapied class of biologics in commercial insurance. Aetna's step-therapy policy for this class typically requires documented failure of one or more conventional disease-modifying agents — and sometimes a prior biologic in a different mechanism class — before it will authorize a TNF inhibitor. A step-therapy denial means Aetna's reviewer determined that the required prior steps were not documented, not completed, or not reflected in the authorization submission.

Step-therapy denials are among the most consistently reversible denial types when the medical record actually documents the required prior treatments. The appeal process turns on documentation quality, not clinical disagreement.

## Federal and State Appeal Rights

• Internal appeal: File within the deadline on your denial notice. Request Aetna's complete step-therapy criteria so you know exactly which prior treatments are required and in what sequence.
• Step-therapy override statutes: Many states have enacted laws requiring insurers to grant step-therapy exceptions when: (a) the required prior therapy is contraindicated for you, (b) you have already tried and failed it, or (c) the required step would cause harm or significant delay. Confirm whether your state's law applies to your plan type.
• Peer-to-peer review: Your prescriber should request a peer-to-peer call with Aetna's reviewing medical director. This is often the fastest resolution path, particularly when the prior treatment history is well-documented.
• External review (ACA §2719 / ERISA §503): After internal exhaustion, escalate to independent external review within approximately four months of the final adverse determination.
• Expedited review: Available if delay in accessing the TNF inhibitor would seriously jeopardize your health.

## What to Gather

• Prior treatment chronology: A dated list of every conventional therapy (e.g., methotrexate, sulfasalazine, or other disease-modifying agents relevant to your diagnosis) tried before the TNF inhibitor request, with start dates, end dates, doses escalated, and documented outcomes — inadequate response, intolerance, or contraindication.
• Chart notes for each step: The actual office visit notes, lab results, and pharmacy records supporting each entry in the prior treatment chronology.
• Contraindication documentation (if applicable): If a required step was skipped because it was clinically contraindicated for you, provide the chart notes and prescriber explanation.
• Diagnosis and severity documentation: Current disease-activity measures, specialist notes, and relevant objective findings showing the condition for which the TNF inhibitor is needed.
• Prescriber step-therapy letter: A letter from your specialist explicitly mapping each Aetna step-therapy requirement to the corresponding chart evidence, and explaining why proceeding to the TNF inhibitor is now appropriate.

## Criteria-Mapping Structure

Download Aetna's Clinical Policy Bulletin for the relevant TNF inhibitor. List each step in the required therapy sequence. For every step, write: (1) the treatment required, (2) whether you tried it, (3) the chart date and note confirming the trial, and (4) the documented outcome. Submit this table with your appeal. A complete table removes the reviewer's basis for upholding the denial.